85 FR 54 pgs. 15789-15790 - March 10 Through April 30, 2020, Public Meetings; Postponement, Cancellation, or Remote Only
Type: NOTICEVolume: 85Number: 54Pages: 15789 - 15790
Pages: 15789, 15790Docket number: [Docket Nos. FDA-2020-N-0001, FDA-2020-N-0255, FDA-2020-N-0256, FDA-2020-N-0259, FDA-2018-N-4337]
FR document: [FR Doc. 2020-05743 Filed 3-18-20; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA-2020-N-0001, FDA-2020-N-0255, FDA-2020-N-0256, FDA-2020-N-0259, FDA-2018-N-4337]
March 10 Through April 30, 2020, Public Meetings; Postponement, Cancellation, or Remote Only
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration is announcing that certain meetings involving the Center for Drug Evaluation and Research (CDER) from March 10 through April 30, 2020, are postponed, cancelled, or modified to take place remotely.
DATES:
For dates that have been either postponed or cancelled, see table 1 in the SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Kim Thomas, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6282, Silver Spring, MD 20993-0002, 301-796-2357, Kimberly.K.Thomas@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
Certain public meetings involving CDER from March 10 through April 30, 2020, are postponed, cancelled, or modified to take place remotely due to extenuating circumstances. The meetings that are postponed or canceled as part of this notice are listed in table 1. If a meeting is rescheduled, information about the rescheduled meeting will be provided in the future. The meeting that will no longer take place in person and instead take place by webcast only as part of this notice is listed in table 2.1
Footnotes:
1 ?Up-to-date information about public meetings involving CDER is available on the internet at https://www.fda.gov/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs.
[top]
| Meeting type | Meeting title | Original meeting date | Docket No. | Federal Register citation |
|---|---|---|---|---|
| Public Meeting | Patient-Focused Drug Development for Stimulant Use Disorder | Mar. 10, 2020 | FDA-2020-N-0259 | 85 FR 8877, Feb. 18, 2020. |
| Public Meeting | Patient-Focused Drug Development for Vitiligo | Mar. 30, 2020 | FDA-2020-N-0255 | 85 FR 8004, Feb. 12, 2020. |
| Public Meeting | Scientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical Trials | Apr. 16, 2020 | FDA-2020-N-0001 | 85 FR 14207, Mar. 11, 2020. |
| Public Meeting | Prescription Drug User Fee Act of 2017; Electronic Submissions and Data Standards | Apr. 22, 2020 | FDA-2018-N-4337 | 85 FR 6547, Feb. 5, 2020. |
| Meeting type | Meeting title | Original meeting date | Docket No. | Federal Register citation | Remote information |
|---|---|---|---|---|---|
| Public Meeting | United States Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | Apr. 3, 2020 | FDA-2020-N-0256 | 85 FR 13659, Mar. 9, 2020 | https://www.fda.gov/drugs/news-events-human-drugs/health-canada-and-fda-joint-public-consultation-international-council-harmonisation-technical-0. |
Dated: March 16, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-05743 Filed 3-18-20; 8:45 am]
BILLING CODE 4164-01-P